World News: 13:30 GMT Friday 15th March 2019. [Hagens Berman Sobol Shapiro LLP via Globe Newswire via SPi World News]
SAN FRANCISCO, March 15, 2019 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Corbus Pharmaceutical Holdings, Inc. (NASDAQ: CRBP) to the in the securities class action pending in the United States District Court for the District of Massachusetts. If you purchased or otherwise acquired Corbus Pharmaceutical securities and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information about the case click
or contact Reed Kathrein, who is leading the firm’s investigation, by calling or emailing
According to the complaint, during the class period Defendants misled investors about Corbus Pharmaceutical’s drug candidate Lenabasum by, among other things, changing the primary efficacy endpoint of the Lenabasum study after the Company was unblinded to the results and extending the efficacy readout to 16 weeks which was a full 4 weeks after patients were off the therapy.
On February 28, 2019, a contributor published an article highlighting the change and other potentially adverse matters.
This news drove the price of the Company’s shares down almost 16% to close at $6.94 that day.
“Among other matters, we’re focused on investors’ losses and whether Defendants may have misled investors concerning the Lenabasum study,” said Hagens Berman partner Reed Kathrein.
Globe Newswire: 13:30 GMT Friday 15th March 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.